Status:
RECRUITING
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Prostate Cancer Stage I
Eligibility:
MALE
40-100 years
Brief Summary
In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening. Among them, many had low-risk PC, which is very likely latent in nat...
Detailed Description
At the Department of Urology, NTUH, we have established a largest Chinese AS/WW cohort, which were prospectively collected since 2013. There were already 280 AS and 100 WW patients. Most AS patients h...
Eligibility Criteria
Inclusion
- Historically or cytologically confirmed adenocarcinoma of prostate.
- Have or ever received active Surveillance as the main conservative management at NTUH (National Taiwan University Hospital).
- Have or will receive prostate biopsy to confirm tumor progression after the diagnosis of prostate cancer.
Exclusion
- Have received systemic chemotherapy, pelvic radiotherapy or androgen deprivation therapy (ADT) before the obtainment of pathological specimen from prostate operation or biopsy.
- Subjects who disagree with signing the informed consent.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03789253
Start Date
January 2 2019
End Date
July 31 2030
Last Update
August 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University
Taipei, Taiwan, 10002